MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan
暂无分享,去创建一个
[1] D. Silverman,et al. Radiation dosimetry results for zevalin radioimmunotherapy of rituximab‐refractory non‐hodgkin lymphoma , 2002, Cancer.
[2] Daniel H. S. Silverman,et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma , 2000, European Journal of Nuclear Medicine.
[3] W. Nelp,et al. Radiation absorbed dose from indium-111-CYT-356. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] G. Denardo,et al. Prediction of myelotoxicity using semi-quantitative marrow image scores. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] S. Shen,et al. Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein. , 2005, Cancer biotherapy & radiopharmaceuticals.
[6] J G Kereiakes,et al. In vivo quantitation of lesion radioactivity using external counting methods. , 1976, Medical physics.
[7] M. Khazaeli. Quantitation of mouse monoclonal antibody and human anti-mouse antibody response in serum of patients. , 1989, Hybridoma.
[8] D. Podoloff,et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] G. Wiseman,et al. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. , 2003, Cancer biotherapy & radiopharmaceuticals.
[10] G. Martinelli,et al. High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment , 2007, Journal of Nuclear Medicine.
[11] Michael G Stabin,et al. DECAY DATA FOR INTERNAL AND EXTERNAL DOSE ASSESSMENT , 2002, Health physics.
[12] P. N. Badenhorst,et al. Quantification of the distribution of 111In-labelled platelets in organs , 2004, European Journal of Nuclear Medicine.
[13] S. Srivastava,et al. Radiolabeled Monoclonal Antibodies for Imaging and Therapy , 1988, NATO ASI Series.
[14] Hervé Watier,et al. From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.
[15] M. Prescott,et al. Uptake, localization, and dosimetry of 111in and 201tl in human testes. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] I. Buvat,et al. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. , 2008, Cancer biotherapy & radiopharmaceuticals.
[17] L. Taylor. INTERNATIONAL COMMISSION ON RADIOLOGICAL UNITS AND MEASUREMENTS (ICRU) , 1966 .
[18] Herbert Malamud,et al. MIRD Primer for Absorbed Dose Calculations , 1989 .
[19] P. Conti,et al. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] A. Brill,et al. Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18. , 1998, Journal of Nuclear Medicine.
[21] G. Denardo,et al. Quantitative Pharmacokinetics of Radiolabeled Monoclonal Antibodies for Imaging and Therapy in Patients , 1988 .
[22] D. Podoloff,et al. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. , 2003, Cancer biotherapy & radiopharmaceuticals.
[23] Michael G Stabin,et al. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] F. Appelbaum,et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. , 1987, Blood.
[25] J A Parker,et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2001, Critical reviews in oncology/hematology.
[26] S. Shen,et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] B. Wessels,et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] G Sgouros,et al. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] J. Eary,et al. Preliminary validation of the opposing view method for quantitative gamma camera imaging. , 1989, Medical physics.
[30] I. Bernstein,et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.
[31] W. S. Snyder,et al. Report of the task group on reference man , 1979, Annals of the ICRP.